Furthermore, the reduction in the expression of key angiogenic genes (i.e., Pecam1, Vcam1, Flt1, and Kdr) indicates that rifaximin effectively inhibits the angiogenic switch, which is critical for tumor growth and metastasis. This evidence concerns the gene KDR and neoplasm.